Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)
Biotech investors faced a dense catalyst calendar on Tuesday, December 9, 2025, as new U.S. Food and Drug Administration (FDA) signals on cell and gene therapy, fresh designations in hematologic cancers and high‑impact clinical data from the American Society of Hematology (ASH) meeting collided with a wave of secondary offerings. Despite a string of double‑digit movers, the sector finished in the red. The iShares Nasdaq Biotechnology ETF (IBB) closed around $167, down roughly 1.6% on the day, while the SPDR S&P Biotech ETF (XBI) slid about 1.8%. By contrast, the SPDR S&P 500 ETF (SPY) was essentially flat and the